Susan Hyde
29 July 2026
Susan reflects on her journey with MS from a young age, her diagnosis story and the importance of building a strong support network.
Susan reflects on her journey with MS from a young age, her diagnosis story and the importance of building a strong support network.
The research, funded through MS Australia’s mid-year grants round and based at The Florey Institute of Neuroscience and Mental Health, will investigate how the brain naturally produces myelin, the protective coating around nerve fibres that is damaged by MS.Â
Through its mid-year grants, MS Australia is investing early in promising research ideas and researchers at the start of their careers, to help drive the next wave of innovation and leadership in MS research.
CEO Rohan Greenland calls on the Australian Government to significantly boost support for pain and neurological research this National Pain Week, explaining why pain experienced by people living with MS is under-recognised and, too often, inadequately treated.
New research shows AHSCT was superior to cladribine and alemtuzumab in reducing relapses in people with relapsing remitting MS.
On Thursday 16 July, the Australian Government announced that Ocrevus and Kesimpta would remain on the Pharmaceutical Benefits Scheme (PBS).
The Australian Government has confirmed that Ocrevus and Kesimpta will remain available through the Pharmaceutical Benefits Scheme (PBS), meaning thousands of Australians living with MS can continue to access these life-changing treatments.Â
MS Australia warmly welcomes the announcement from the Minister for Health and Aged Care, the Hon Mark Butler MP, that Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) will remain available through the Pharmaceutical Benefits Scheme (PBS).
Multiple disease-modifying therapies (DMTs), Ocrevus (ocrelizumab) and Kesimpta (ofatumumab), are at risk of being withdrawn from the Pharmaceutical Benefits Scheme (PBS), as a consequence of government-driven policy-related price reductions.